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Dental pulp is an accessible source of multipotent mesenchymal stromal cells (MSCs).The perspective role of dental pulp stem cells
(DPSCs) in regenerative medicine demands an in vitro expansion and in vivo delivery which must deal with the safety issues about
animal serum, usually required in cell culture practice. Human platelet lysate (PL) contains autologous growth factors and has been
considered as valuable alternative to fetal bovine serum (FBS) in cell cultures. The optimum concentration to be added of such
supplement is highly dependent on its preparation whose variability limits comparability of results. By in vitro experiments, we
aimed to evaluate a standardised formulation of pooled PL. A low selected concentration of PL (1%) was able to support the growth
and maintain the viability of the DPSCs. The use of PL in cell cultures did not impair cell surface signature typically expressed by
MSCs and even upregulated the transcription of Sox2. Interestingly, DPSCs cultured in presence of PL exhibited a higher healing




than those cultured with FBS. Moreover, PL
addition was shown as a suitable option for protocols promoting osteogenic and chondrogenic differentiation of DPSCs. Taken
together, our results indicated that PL is a valid substitute of FBS to culture and differentiate DPSCs for clinical-grade use.
1. Introduction
Dental pulp stem cells (DPSCs) are multipotent stromal/
mesenchymal stem cells (MSCs) representing a source, free
of ethical issues, of replacement cells worthwhile in human
therapies. From a clinical point of view, it is necessary to avoid
any immunological reaction to the xenogenic material; then
the investigation on xeno-free ex vivo expansion of MSCs is
highly encouraged. Many platelet derivates were tested so far
in different forms for cell culture to replace animal serum
supplementation. Currently, the use of human platelet lysate
(PL) in clinical settings led to many therapeutic successes
including orthopaedic, periodontal, oral, and maxillofacial
surgeries [1]. PL is biocompatible and has no risk of trans-
missible viral disease or prionic contamination. Platelet con-
centrates can be prepared by buffy coat or platelet-rich plasma
(PRP)method [2], even from expired blood derivates. Freeze-
and-thaw cycles, sonication, and thrombin/CaCl
2
activation
have been used to obtain PL [2]. The variability in PL man-
ufacturing influences the content of main growth factors
(GFs) that will be available in cell culture, such as PDGF
isoforms, TGF-𝛽1, and also VEGF, HGF, and bFGF. The
inconsistency of the results makes PL functionality in vitro
still not exhaustively explored. Furthermore, specific and
optimal culture conditions will be searched [3, 4] especially
for MSCs [5].
DPSCs received great attention for their osteogenic
potential; besides they demonstrated an angiogenic potential
[6], a commitment to melanogenesis [7], differentiation in
neurons [8], and islet-like aggregates formation [9].The tran-
scriptomes and cytogenetical stability of DPSCs expanded
under PL and FBS were previously compared and revealed
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similar profiles [10]. Also CFU-potential, the immunophe-
notype, and trilineage differentiation according to MSC
requisites were comparable [10]. 5% PL was defined as the
concentration for increased cellular proliferation and for
good mineralisation in vitro for DPSCs [10–12]. In addition,
the same concentration was used to seed DPSCs on bio-
materials, showing positive effects on regeneration in vivo
[11]. Often 10% PL inhibited the proliferation of DPSCs.
Interestingly, DPSC cultures in PL had a higher ALP activity
compared to FBS [11, 12]. We initially combined different
assays to select an optimal PL concentration for DPSCs
growth, by evaluating different cell health indicators, such as
membrane permeability, cell division, and metabolic activity.
The comparison between FBS and the selected PL concen-
tration for mesenchymal stem cell capacity was evaluated by
surface marker expression and gene expression of relevant
transcriptional factors.
We focused on PL effects on repairing properties of
DPSCs by performing in vitro migration and survival assay.
Finally, we introduced PL in osteogenic and chondrogenic
inducer media in order to evaluate its effect on DPSCs
differentiation.
We characterised a standardised commercially available
human allogenic platelet lysate as an attractive candidate
for in vitro culture of DPSCs [10]. The use of this safe,
quality-controlled, and potentially advantageous supplement
could establish a preparatory study for regenerative medicine
applications.
2. Materials and Methods
2.1. DPSCs Source and Cell Culture. Human-impacted third
molarswere extracted from20-year-old healthy patients from
Calabrodental Clinic (Crotone). All donors signed a written
informed consent according to the Ethical Committee policy.
To isolate DPSCs, the obtained normal teeth were washed in
saline solution containing antibiotic solutions and immedi-
ately transferred to the cell culture laboratory. Mesenchymal
stem cells were isolated under sterile conditions according to
a previously published method [13, 14]. Briefly, pulp tissues
were isolated and washed several times with PBS and further
cut with a scalpel into small pieces. Subsequently, the whole
small pieces were dissociated to have single cell suspension
by enzymatic digestion, using 3mg/mL type I collagenase
and 4mg/mL dispase (Sigma-Aldrich, Saint Louis) in Hank’s
Balanced Salt Solution (Invitrogen, Carlsbad). Then, samples
were incubated for 1 h at 37∘C in agitation and the digest
was diluted in alpha-minimal essential medium (𝛼-MEM,
Gibco, Grand Island) supplemented with 10% FBS (Gibco,
Grand Island) and centrifuged at 300×g for 5min. The
pellet was finally resuspended in fresh medium, seeded in
culture dishes, and incubated at 37∘C 5% CO
2
. DPSCs were
routinely expanded in growth medium consisting of 𝛼-MEM
supplemented at 10%FBS. Trilineage differentiation ofDPSCs
was early assessed and cell stocks were cryopreserved. Two
donorswere used for the study. PLwas purchased fromSclavo
Diagnostics (Sovicille).
2.2. Viability Assays. For live/dead imaging, DPSCs were
grown on sterile cover slides 24 × 24mm and cultured for
5 days in FBS or PL media. After formalin fixation, the
cells were stained with a solution of Calcein AM-EthD-
III (Biotium, Hayward) according to the kit indications.
Epifluorescent signal was detected and relative images were
acquired through SP5microscope (Leica,Wetzlar).Metabolic
activity of DPSCs was assessed by PrestoBlue (Molecular
Probes, Eugene) assay. Briefly, cryopreserved DPSCs were
thawed and resuspended in 𝛼-MEM containing FBS at 10%
or PL at 5%, 2%, and 1%. Cells were seeded at 2500 cell/well
in one 96-well plate for each analysed time point; more
than 6 wells were replicated for each condition. An aliquot
of fresh medium was provided to the plates that were
cultured for more than 4 days. The PrestoBlue reagent was
incubated as supplier instruction to a final volume of 100𝜇L;
after 2 hours the collected supernatant was measured for
absorbance with Multiskan GO (Thermo Fisher, Waltham)
spectrophotometer (570–600 nm). An additional control was
set using human serum (HS) 10%. For viable cell counts,
the samples were trypsinized after 3 days or 3 weeks and
measured by ADAM-MC (AlphaMetrix, Rödermark) system
to evaluate cell membrane permeability by dye exclusion.
2.3. Flow Cytometry. To investigate cellular proliferation,
DPSCs were labelled with 5 𝜇Mof 5-chloromethylfluorescein
diacetate (CMFDA) in 𝛼-MEM for 45min at 37∘C CO
2
.
Cells were washed in medium and seeded at 105/well in
a 12 well-plate, in duplicate, for different time points (2,
3, and 4 days). Cytoplasmic amount reduction of the dye
was measured using NAVIOS flow cytometer (Beckman
Coulter, Brea). The data were analysed with FlowJo software.
For immunophenotype analysis, cells cultured for 1 week
with 10% FBS or 1% PL were trypsinized and aliquoted in
FACS tube. Cells were washed twice with PBS 0,1% BSA.
To limit unspecific binding, a blocking step is performed by
resuspension of the pellets with PBS 1% BSA for 15min. Cells
were stained on ice for 1 h with saturating concentrations
of primary conjugated antibodies diluted 1 : 50 in PBS 0,1%
BSA. CD13-PE (mouse IgG1), CD29-APC (mouse BALB/c
IgG1), CD44-FITC (mouse IgG2b), CD45-APC-H7 (mouse
IgG1), CD73-FITC (mouse IgG1), CD90-PE (mouse BALB/c
IgG1), and CD105-APC (Mouse BALB/c IgG1) monoclonal
antibodies purchased from BD (Franklin Lakes) and CD146-
PE (mouse IgG1), CD34-FITC (mouse IgG2a), and HLA-
DR-PE (recombinant human IgG1) monoclonal antibodies
purchased from Miltenyi Biotec (Bergisch Gladbach) were
used to define the MSC panel as previously described [15].
At least 10000 events were counted for each sample.
2.4. Real-Time PCR. To analyse cell differentiation state,
gene expression was analysed as previously described [15,
16]. Briefly, RNA samples were obtained after extraction
with PureLink RNA mini kit (Thermo Fisher, Waltham)
following the manufacturer’s instruction. Total RNA was
quantified through spectrophotometry and 500 ng of RNA
was subjected to reverse-transcription reaction using the
High Capacity RNA-to-cDNA Kit (Applied Biosystem,
Foster City). One microliter of cDNA was amplified by
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real-time PCR with the Power SYBR green PCR Master
Mix (Applied Biosystem, Foster City). Real-time PCR reac-
tions were carried out in a PikoReal 96 (Thermo Fisher,
Waltham) apparatus with the following conditions: initial
denaturation step at 95∘C for 10min, followed by 40 cycles
of 10 s at 95∘C and 1min at 60∘C. The specificity of PCR
products was checked by analysis of melting curves. The
expression of each gene was determined from the Ct value,
and relative expression levels were calculated using the ΔΔCt
method after normalisation to the expression of the HRPT
housekeeping gene. All primer pairs sequences are listed
in Table S1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/7230987.
2.5. Wound Scratch Assay. For scratch assay, DPSCs were
seeded and grown until confluence in 35mm dishes. An
in vitro wound (600𝜇m average size) was created in the
monolayer by scraping it over the total diameter with a sterile
10 𝜇L pipette tip. Dishes were washed twice in 𝛼-MEM to
smooth the scratch edges and remove any suspended cells.
Cultures were refed with fresh complete medium containing
10% FBS or 1% PL. Reference markings were made on the
external surface of the dishes to identify scraped zones to
be photographed 2 hours and 24 hours after scratch. To
quantify the wound healing capacity, images were manually
analysed. A digital rectangle zone free of cells and centred on
the wound breadth was set on 2-hour controls and thus was
superimposed on the corresponding 24-hour images. Cell
dense regions were drawn trough polygonal selection tool
and measured by ImageJ software. Multiple selections were
summed and healing was determined as percentage of the
open (wound) area at 24 hours.
2.6. Chemotaxis Assay. Anunder-agarosemethodwas adapt-
ed from Vogel et al. [17] Briefly, sterile melt 1% agarose in
𝛼-MEM was poured in 60mm dishes. Three equally distant
wells (≈5mm) were made by pressing a sterile tip on the
agarose gel surface. The gel was equilibrated overnight in 𝛼-
MEM. DPSCs were harvested at exponential phase, washed
in 𝛼-MEM, and seeded in the central well at concentration of
3.5 × 104 cells/70𝜇L. A volume of 70 𝜇L medium containing
10%FBSor 1%PLwas added to the rightwell in order to create
a chemoattractant gradient in culture, while a same volume
of 𝛼-MEM was added to the left well as negative control of
chemotaxis. After 24 hours of incubation at 37∘C 5% CO
2
,
both left and right wells were refilled of their content. At 48
hours, the dishes were gently washed and fixed in formalin
5% overnight at 4∘C. Four pictures (10x zoom) were taken at
24 hours for quantitative analysis at each interwell’s zone.The
images were tiled and cell number was manually counted in
ImageJ software. Only cells completely outside the well and
under the agarose were considered. The counted number of
migrated cells is corrected subtracting the number of cells
which moved towards the negative control well.





on DPSCs was tested in dose-
dependent manner after 1-hour exposition in basal medium
(BM) which consisted of 𝛼-MEM. PrestoBlue assay was
performed after 48 hours to detect the challenge on viability
[18, 19]; therefore an EC
50
of 500𝜇M was established for
following experiments (Fig. S3). For cell survival test, DPSCs
were seeded as 3.5 × 104DPSCs/well of a 96-well plate and
left to adhere in complete media, 10% FBS or 1% PL. On the





was added in basal medium (BM) or completemedium
(CM) containing 10% FBS or 1% PL. Subsequently, cells were




dilution was replaced with new complete medium. After 6
hours, at 37∘C 5% CO
2
, PrestoBlue was incubated for 2 hours
and its absorbance read. Alternatively, DPSCs were seeded in
12-well plates, treated as above, and trypsinized 6 hours later
to perform viable counting by ADAM-MC.
2.8. In Vitro Osteogenic Differentiation. For osteogenic differ-
entiation, growing cells were detached and seeded subcon-
fluently in 60mm Petri dishes. At 85–90% of confluence, cell
medium was changed to osteogenic medium composed of 𝛼-
MEM with glutamine (Gibco, Grand Island), 1% PL, 0,2mM
L-ascorbic acid-2-phosphate (Sigma-Aldrich, Saint Louis),
100 nM dexamethasone (Sigma-Aldrich, Saint Louis), 10mM
𝛽-glycerophosphate (Sigma-Aldrich, Saint Louis), penicillin-
streptomycin solution (Sigma-Aldrich, Saint Louis), and
0.25mg/mL amphotericin B (Sigma-Aldrich, Saint Louis).
The positive control group medium included 20% FBS in
place of PL. Osteogenic inductionwas performed for 4weeks,
replacing media twice a week.
The differentiation was assessed by Alizarin red, quanti-
fied via spectrophotometry (405 nm) after dissolution in 10%
acetic acid, and analysed by real-time PCR (primer listed in
Table S1) for gene expression levels of osteogenic markers.
2.9. In Vitro Chondrogenic Differentiation. For chondrogene-
sis differentiation, DPSCs were initially detached and seeded
subconfluently in 60mm dishes. At 85–90% of confluence,
growth medium was changed to chondrogenic medium
composed ofDMEMHighGlucose (Gibco,Grand Island), 1%
PL, ITS + 1 Supplement (Sigma-Aldrich, Saint Louis), 100 nM
dexamethasone (Sigma-Aldrich, Saint Louis), 50mg/mL L-
ascorbic acid-2-phosphate (Sigma-Aldrich, Saint Louis), and
freshly added 10 ng TGF-𝛽1 (Miltenyi Biotec, Bergisch Glad-
bach). The positive control groups’ medium did not include
PL in the formula. Chondrogenic induction was performed
for 3 weeks, replacing the media twice a week. Alcian blue
staining was extracted in acetic acid and its relative quantifi-
cation was performed by spectrophotometry (620 nm). For
micromass culture 5 × 105 cells were pelleted at 300 g and
washed in 1mL of medium free of TGF-𝛽1 and then left
to aggregate in incubator in 1mL of chondrogenic medium
(with TGF-𝛽1). Chondrogenic induction was performed for
3 weeks, replacing the media twice a week.
2.10. Histology. In several wound scratch assays, the scraped
dishes were fixed and stained with eosin for qualitative
late time points (3 days and 7 days) analysis and storage
of samples. For osteogenesis confirmation, the dishes were
fixed in 10% formalin for 15min, washed in distilled water,
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and stained with Alizarin red (5mg/mL) for 30min. The
samples were then washed several times with distilled water
until clarity. For chondrogenesis confirmation, wells were
fixed in 10% formalin for 15min, washed in distilled water,
and stained with Alcian blue pH 2.5 (Bio-Optica, Milan)
following the supplier’s indications. Finally, the samples were
washed twice in abundant distilled water. Chondrogenic
micromasses were formalin-fixed overnight, embedded into
agarose block, and processed for classical histology. Sec-
tions of 3,5 𝜇m thickness were prepared using microtome
(Leica). The slides were finally stained with Alcian blue
and counterstained in Azocarmine Red (Bio-Optica, Milan).
All histological samples were photographed for qualitative
analysis using optical microscopes and color cameras (Leica
suite).
2.11. Statistics. All the plots were edited in GraphPad Prism
software. The specific statistical method to interpret the
graphs is described within the individual captions. Differ-
ences were considered statistically significant when 𝑃 < 0.05.
∗
𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001; ∗∗∗∗𝑃 < 0.0001.
3. Results
3.1. Viability and Proliferation. The effect of different concen-
trations of PL ranging from5% (high) to 1% (low)was initially
compared to 10% FBS by observing viability parameters.
The imaging of DPSCs, grown at high density for 5 days
and marked with fluorescent live/dead staining, reported a
high viability rate in all compared conditions, with only rare
detection of dead cells across the whole sample (Figure 1(a)).
Slightly morphological changes appeared in 2% (mid) and
5% (high) concentrations of PL, where long intercellular pro-
cesses and circular association were visible at minor density.
After 3 days of culture, no statistically significant difference
among the conditions was shown, despite the fact that the
average number of cells grown with 5% PL seemed to be
lower (Figure 1(b)). Through relative viability quantification
of the counted samples, we confirmed the live/dead staining
qualitative results (Figure 1(c)). Viable counts of long-term
cultures showed that 1% PL is still competitive in viability
with respect to 10% FBS (Figure 1(d)). Different trends of
metabolic activity were emphasised instead by PrestoBlue
assay (Figure 1(e)). In particular, compared to FBS, both 1%
and 2% PL showed a higher metabolic rate during the first
days of culture, while the 5% PL never outdid FBS. Despite
the fact that 1% PL and 2% PL showed a similar trend, 1%
concentration brought fewer changes during the last days and
presented more similarity to FBS controls until the plateau
growth phase (10 days). To further assess if this low PL
concentration was sufficient to promote DPSCs proliferation,
cells within first days of culture were analysed by flow
cytometry for the CMFDA tracer (Figure 1(f)). CMFDA
labelling of DPSCs highlighted a significant higher rate of
proliferation in 1% PL compared to 10% FBS during 48 hours
from seeding (Figure 1(g)).
3.2. Stem Cell Properties. To verify the identity of MSCs
after the switch to 1% PL as supplement in cell medium,
the DPSCs were analysed for MSCs surface markers by flow
cytometry. The immunophenotype of DPSCs cultured in 1%
PL resulted in coexpression of the obligatory ISCT markers
[20] CD73, CD90, and CD105 and also the positive signal
by CD13, CD29, CD44, and CD146 (Figure 2(a)), while it
did not express negative markers such as CD34, CD45, and
HLA-DR (Fig. S1). Intriguingly, the half population of DPSCs
increased their CD146 expression when cultured in 1% PL.
Compared to their controls, fluorescence geometric mean of
PL is higher for CD13 and CD73 (data not shown). OCT4,
Nanog, and Sox2 pluripotency markers were evaluated by
quantitative PCR (Figure 2(b)). Samples cultured with PL
until 6 days maintained the level of transcription of OCT4
compared to those cultured with FBS. On the other hand,
PL supplementation timely increased Sox2 transcripts levels,
while Nanog levels were significantly higher only at the last
time point.
3.3. Migration Capacity. Platelet-derived GFs are involved in
woundhealing process [4]; thuswe performed a scratch assay.
Capturing images of different time points, we highlighted
a greater level of wound closure for DPSCs scraped and
then maintained in low-PL medium rather than in FBS
medium.The enhanced cellmigration in PL cultures from the
wound edges is clearly evident 24 hours later (Figure 3(a)).
Moreover, DPSCs cultured in low-PL medium continued to
reduce the gap space after 3 and 7 days with a faster rate
in comparison to FBS cultures (Figure 3(b)). One week after
scratch, DPSCs in 1% PL were able to fully close the open
wound area (Figure 3(c)). We also microscopically detected
cell division in the wound space (Fig. S2), thus not restricting
the repairing stimulation of PL to the migration of cells that
were already present before the injury. Moreover, we counted
the number of cells migrated at 24 h to have a quantitative
result (Figure 3(d)). To address the question if this migrating
ability can be associatedwith the solubleGFs contained in PL,
we performed an under-agarose chemotaxis assay. After 24
hours, a conspicuous number of DPSCs positively responded
to chemoattraction byPL,while very few cellsmigrated under
the agarose gel to FBS containing compartment (Figure 3(e)).
3.4. Resistance to Cellular Damage Induced by H2O2. The





was analysed either by PrestoBlue assay (Figure 4(a))
or viable counting (Figure 4(b)) after 6 hours from the
treatment. The presence in medium of PL before, during,
and after treatment (complete media, CM) marked a non-
significant difference output between untreated and treated
samples, thus neutralising or rescuing the cells from the
reactive oxygen species (ROS) action. On the contrary, the
continuative presence of FBS in the wells (CM) was not









in basal media (BM) incubation reduced their vital activity
measured by PrestoBlue reagent and were affected in own
membrane integrity noticeable by dye exclusion cell counts.
3.5. Bony and Cartilaginous Differentiation. To test the suit-
ability of PL for in vitro differentiation protocols, we basically










































































































Figure 1: Effect of PL on the growth of DPSCs. (a) Representative images from live/dead fluorescence assay after 5 days of culture in different
culture conditions. Green = live; red = dead. (b) Viable counts quantified by ADAM system after 3 days of culture. Data shown as mean +
SD, 𝑛 = 3, statistical significance according to 2-way ANOVA method (𝑃 < 0.05); ns: not significant. (c) Statistic values (average viability
percentages) derived from samples in (b). (d) Viability after long-term culture of 3 weeks. Data shown as mean + SD, 𝑛 = 2. ns: not significant
according to unpaired 𝑡-test. (e) Cell growth activitymeasured by PrestoBlue assay. Data shown asmean + SD, 𝑛 = 2. (f) CMFDAproliferation
assay. Time-course comparing FBS and PL-selected condition. (g)Quantification ofMFI derived from samples in (f). Statistics based on 2-way
ANOVA method (∗𝑃 < 0.05). ns: not significant.
substituted 20% FBS to 1% PL for osteogenesis of DPSCs;
otherwise we added 1% PL to the serum-free formula for
chondrogenesis. Results from Alcian blue staining showed
the deposition of proteoglycans in both 2D (monolayers,
Figures 5(a)–5(d)) and 3D conditions (micromasses, Fig-
ures 5(g) and 5(h)), confirming that PL did not impair
chondrogenic differentiation of DPSCs. These results were
confirmed by spectrophotometric measurement of Alcian
blue complex formation (Figures 5(e) and 5(f)). Besides, FBS
replacement with PL did notmodify the formation of calcium
deposits stainable by Alizarin red (Figures 6(a)–6(e)). Again,
the differentiating condition in PL was statistically different
compared to its respective undifferentiated control, as well
as FBS condition (Figures 6(c) and 6(f)). Regarding genes
analysis, PL samples showed at the end of differentiation
a higher ALP expression compared to the respective basal
state, a situation that did not correspond in FBS controls
(Figure 6(g)). While FBS seemed to upregulate OSC and
DMP-1 osteoblastic markers in 4 weeks in differentiating
samples, we cannot affirm the same for PL differentiated
cultures, in fact, showing lower relative levels at the same time
of analysis (Figure 6(g)). RUNX2 transcription factor had a
comparable fold increase in FBS samples as well as in PL
samples (Figure 6(g)).
4. Discussion
So far, it has been observed that the proliferation rate of
MSCs cultured in PL-supplementedmediumwas higher than
that of those cultured in FBS-supplemented medium [21, 22].
The used concentrations of PL usually ranged from 10% to
lesser than 1%, but the great heterogeneity of the results,
mostly due to the preparation of PL, still delays the finding
of the best concentrations to be used for specific cell type
and application. The highest percentages, for example, 10%
PL, often were not suitable to culture or expand the cells
[11, 12], while 5% PL was the most tested and promising
concentration for MSCs [23–26]. Here, we observed a good
viability for 5% PL cultures but at the same time we noted
resistance to trypsinization at this concentration. Partially, in
accordance with other reports [27, 28], the DPSCs had easier
and faster detaching from the plate compared to FBS when
the concentrationswere lower than 5%PL.At 1%PL,we could
see that DPSCs attached quicker than FBS after cell seeding.
Using the same low-PL concentration, DPSCs displayed a
good viability and proliferation profile. Already Lee et al.
showed the feasibility of low-percentage supplementation of
PL for DPSCs growing and osteogenic differentiation [29].
On the base of our results, we choose 1% PL as selected
concentration to adopt in culture for characterising DPSCs
stemness, multipotency, and role in repair.
The immunophenotype of DPSCs cultured in PL was
completely faithful to MSCs markers panel, confirming pre-
vious studies by colleagues [10]. Many stem cell lines express
CD13; among the MSCs sources it is particularly present in
oral tissues, while it is absent in bone marrow compartment
[30]. The lack of this receptor was shown to impair in vitro
adhesion to several ECM proteins, migration, and invasion
[31]. Our PL cultures of DPSCs consistently expressed CD13.
CD13 together withCD29 andCD73 [32] andCD44 [33] were
associated with enhanced migrating phenotype of MSCs.
CD146 is an endothelial and pericytemarker [34]. It is known























































































































































































































































































































































































































































































































Figure 2: Stem cell markers comparison between FBS and PL cultures of DPSCs. (a) Immunophenotype for expressed MSC surface markers
by flow cytometric analysis. The number specifies the percentage of gated cells positive for the indicated protein. Data representative of two
experiments. (b) Relative levels of transcripts (fold change) for stemness markers derived from real-time PCR analysis. Statistical significance
determined by 2-way ANOVA (∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001; ∗∗∗∗𝑃 < 0.0001), mean + SD, 𝑛 = 3.
to be downregulated in culture with FBS [35]. Moreover, our
DPSCs expressed the CD146 receptor on their membrane
when cultured in PL in comparison to FBS. This agrees with
recent data about CD146 increased expression by BM-MSC
in PL medium [24]. Both CD13 and CD146 are angiogenic
markers; thus our study generated preliminary data to further
include DPSCs angiogenesis protocols. Embryonic stem cell
markers, in particular transcription factors such as Oct4,
Nanog, and Sox2, were usually thought to have a similar
role in maintenance of stemness also in DPSCs [36–38]. In
general, they are indicative of a more immature phenotype
for MSCs [39]. Nonetheless, it is very hard to understand
the impact of their transcripts levels in DPSCs; an increase
of their expression sustains a proliferating condition by cells.
Our DPSCs cultures in PL sustained a higher gene expression
of Sox2 [40], which also plays a role in migration of DPSCs
[41].
MSCs can be exposed to various chemical or physical
stresses, which may induce a cellular decay. MSCs [42] and
HSCs [43] share with leucocytes the capacity of homing to
damaged sites in several tissues. It is essential that DPSCs
will move to the site of new skeletogenesis or during MSC-
mediated tissue repair. Many migration assays are available
tools for oral regeneration studies [44]. PL was also already
described as efficient in promoting in vitro wound healing
of dermal fibroblast [45], C2C12 mouse myoblasts [46], ker-
atinocytes [47], and other human cells [48]. So far, an indirect
enhanced migration and chemotaxis by BM-MSCs were
induced by coating of platelet lysate on HA/b-TCP scaffolds
[49]. In response to the injury, the DPSCs cultured in PL
improved their ability to fix an induced mechanical damage
such as a wound. In addition, we demonstrated that PL had
a superior chemotactic activity than FBS, a reason which is
likely correlated to the better migration of DPSCs towards



















































Figure 3: In vitro migration capacity of DPSCs is enhanced by PL. (a) Representative images of early time points during the scratch assay.
Images were taken 2 hrs and 24 hrs after the initial scratch and are representative of 3 independent experiments. The cells were fixed and
stained at different endpoints as shown in (b) for 3 days and (c) 7 days. (d) Quantitative analysis of wound healing at 24 hrs after scratch. 100%
is set as open area 2 h time points. Data shown as mean + SD, 𝑛 = 3. Statistical significance determined using unpaired 𝑡-test (∗∗𝑃 < 0, 1). (e)
Quantification of chemotaxis derived from under-agarose assay. Data were collected using 24 h time points light microscope images. Data
shown as mean + SD, 𝑛 = 3. Statistical significance determined using unpaired 𝑡-test (∗∗∗𝑃 < 0.001).
the wounded region. Even though our experimental setting
aimed to show how the healing of a scratched monolayer of
DPSCs involved just the migration mechanism, surprisingly
also cell genesis was active during the reparative process.
Oxidative stress can lead to a wide range of cellular damage,
such as damage to membrane lipids, proteins, and DNA.
It is widely accepted that increasing concentration of free
radicals augmented premature senescence even in vitro [50]
or associated with bone disorders [51]. The platelets are very




which is a modulator and an
efficient inducer of their aggregation [52]. SOD enzyme, also
derived from the platelets, inhibited neutrophils excessive
production in reactive oxygen species (ROS). Despite the role
of platelets in releasing free radicals, their granules contained





, implying a neutralization
action (supported by cell membrane permeability data) or
high-level metabolic recovery (mostly mitochondrial). We
speculate that the quite antioxidant activity detected with PL
couldmainly derive from catalase residues in the preparation
and may be a beneficial protecting feature for MSCs, if this
supplement is used. However, it is not possible to exclude




is an intrinsic capacity
that the cells acquire for the adding of PL. Nonetheless, a
deeper comprehension would be desirable; this effect of PL
we showed was not observable at the same level for FBS.
Moreover, PL is highly requested for cell-based ther-
apies such as tissue engineering and bone and cartilage
regenerative approaches [53]. Chondrogenic and osteogenic
potentials were broadly studied and they were retained and
influenced by PL added in cultures of MSCs [21, 54, 55].
MSCs cultured in 5% PL were seen to spontaneously activate
osteoblastic gene expression [56]. Many authors documented
that appropriate concentrations (i.e., 5% PL) enhanced, in
particular, DPSCs mineralised differentiation and showed
odontogenic potency [11, 12, 24]. The generation of protocols
aimed at chondrogenesis taking advantage of PL is an
expanding field [10, 21, 25, 57, 58], because PL is a rich
source of natural TGF-𝛽 and the regenerative potential of
primary chondroblasts is more restricted. PL was recently






























































































































































on cellular viability is influenced by PL in culture. (a) Metabolic activity of cultures measured by PrestoBlue




. Data are expressed as mean + SD, 𝑛 = 3, derived from 2 experiments. (b) Automatic viable
cell counts after 6 hrs of treatment. Data were normalised to median value of control samples and shown as mean + SD, 𝑛 = 3. To determine
significant results, the unpaired 𝑡-test was performed (∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001; ∗∗∗∗𝑃 < 0.0001). CM, treatment performed in
complete medium; BM, treatment performed in basal medium.




































Figure 5: Effect of PL on chondrogenic differentiation of DPSCs. (a–d) Representative images of DPSC cultured for 21 days in chondrogenic
medium without (a) or with (b) PL. They were positively stained by Alcian blue, while cells maintained in 10% FBS (c) or 1% PL (d) growth
media were not. (e, f) Quantification of Alcian blue by spectrophotometry for assay controls (e) and samples containing PL (f). Significant
levels according to unpaired 𝑡-test (∗∗∗𝑃 < 0.001 and ∗∗∗∗𝑃 < 0.0001). Data shown as mean + SD, obtained from three experiments. (g, h)
Micromass culture of DPSCs showing positive histological staining for chondrogenesis for control (g) as well as the micromasses cultured
with differentiating medium with 1% PL (h).

































































































































































































Figure 6: Effect of PL on osteogenic differentiation of DPSCs. Alizarin red staining on undifferentiated sample cultured in growth medium
with 10% FBS (a) or 1% PL (d) and on samples differentiated with osteogenic medium containing 20% FBS (b) or 1% PL (e). Relative
quantification of the same staining by spectrophotometry. Data shown as mean + SD, 𝑛 = 3 samples. Two different experiments were
performed. Significant levels according to unpaired 𝑡-test (∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001; ∗∗∗∗𝑃 < 0.0001). (g) Relative quantification
of osteogenic markers by real-time PCR on samples derived from the end (28 days) of the differentiating protocol. Data shown as mean + SD,
𝑛 = 3. Significant levels according to unpaired 𝑡-test (∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001; ∗∗∗∗𝑃 < 0.0001).
implemented in scaffolds construction [59] and scaffolds
functionalization procedures [49]. We assessed the compati-
bility for the low-percentage concentration of commercial PL
to be introduced in osteogenic and chondrogenic traditional
protocols for DPSCs. Indeed successful colorimetric detec-
tion was measured either for calcium deposits by Alizarin
or for proteoglycans by Alcian blue. We found an active
gene transcription of the two osteoprogenitor markers ALP
and RUNX2. Even if a total improvement in osteogenesis
after the supplement comparison cannot be assumed at the
selected concentration, the objective advantage of a xeno-
free condition outlines an optimal reason to switch for our
research-grade protocols in whichGFs are delivered fromPL.
Actually, the positive controls conditions for differentiation
were considerably different from testing conditions. Indeed,
a 20% FBS and 1% PL, for the osteogenesis, were compared.
14 Stem Cells International
Respectively, the presence of PL during chondrocytic devel-
opmentwas used instead of absence of serum, suggested from
the historical protocol [60].
Further studies will helpfully evaluate the feasibility of
the use of PL in DPSCs isolation as already described for
BM-MSC [23, 54, 61]. Other elucidations are required for the
immunomodulation function in the presence of standardised
PL preparations, like the one tested in this work. So far, the
dual combination of PL with platelet-poor plasma (PPP) was
shown to be particularly efficient to boost the number of
clonogenic precursors from tissue biopsies, that is, primary
cultures of MSCs from bone marrow, umbilical cord, and
adipose tissue [62, 63].
5. Conclusion
Taken together, our results suggest that human allogenic PL is
a suitable alternative to FBS for expansion and differentiation
of DPSCs in vitro. Furthermore, up to our knowledge, this
is the first study reporting the influence of PL on DPSCs
migration and antioxidant effect during ex vivomaintenance.
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